SCHEMBL4476606

SCHEMBL4476606

CCOC(=O)c1ccc(-c2c3ccccc3nn2Cc2ccccc2F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 3/20 0.50
F2RL3 Q96RI0 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
NR1H2 P55055 2/20 0.47
NR1H3 Q13133 2/20 0.47
NR1I2 O75469 1/20 0.47
NR3C1 P04150 1/20 0.47
TP53 P04637 2/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
RECQL P46063 1/20 0.45
MAPK10 P53779 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 3/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480347 0.84 F2RL3 (0.67) MEN1KMT2AMAPTF2RL3SMN1; SMN2
SCHEMBL4478363 0.82 F2RL3 (0.74) MEN1KMT2AMAPTF2RL3SMN1; SMN2
SCHEMBL4481481 0.74 PTGER4 (0.55) MEN1KMT2AMAPTNR1H2NR1H3
SCHEMBL28495961 0.72 ELANE (0.49) MEN1KMT2AMAPTF2RL3SMN1; SMN2
SCHEMBL23161909 0.72 BUB1 (0.51) MEN1KMT2AMAPTF2RL3SMN1; SMN2
SCHEMBL1851796 0.72 GPR52 (0.47) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL15964665 0.71 CYP1A2 (0.54) MEN1KMT2ASMN1; SMN2TP53POLB
SCHEMBL16082690 0.71 SMN1; SMN2 (0.52) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL20211712 0.71 ALDH1A1 (0.49) MEN1KMT2ASMN1; SMN2TP53POLB
SCHEMBL17611010 0.71 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100516049-C Antiangiogenic agent N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles YUNG SHIN PHARM IND CO LTD (CN) 2009-07-22 CN disclosed
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
CN-1962640-A Novel anti-angiogenic drug N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles YUNG SHIN PHARM IND CO LTD (CN) 2007-05-16 CN disclosed
EP-1659115-A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents Yung Shin Pharm. Ind. Co., Ltd. (TW) 2006-05-24 EP disclosed
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents FLT4, FLT1, KDR MEN1 3429/4885KMT2A 2510/4885MAPT 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.